Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 19/20 | 0.55 |
| ▸ | CDC42BPB | Q9Y5S2 | 19/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 17/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723759 | 0.87 | ROCK1 (0.52) | ROCK1CDC42BPBROCK2PIM1PIM3 | |
| SCHEMBL3723244 | 0.87 | ROCK1 (0.56) | ROCK1CDC42BPBROCK2PIM1PIM3 | |
| SCHEMBL3727115 | 0.80 | ROCK1 (0.50) | ROCK1CDC42BPBROCK2PIM1PIM3 | |
| SCHEMBL20744096 | 0.71 | CDC42BPB (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL30668774 | 0.71 | CDC42BPB (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL3812030 | 0.71 | AKT1 (0.41) | — | |
| SCHEMBL3725000 | 0.71 | BCHE (0.48) | — | |
| SCHEMBL3717638 | 0.70 | ALK (0.47) | ROCK1CDC42BPBROCK2 | |
| SCHEMBL3721139 | 0.70 | ALDH1A1 (0.43) | — | |
| SCHEMBL3723649 | 0.67 | PIM1 (0.52) | ROCK1CDC42BPBROCK2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841304-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| CN-101959887-B | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC | 2013-07-31 | — | — | CN | disclosed |
| EP-2242755-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-12 | — | — | EP | disclosed |
| CN-101959887-A | Pyrrolopyridine as kinase inhibitor | ARRAY BIOPHARMA INC | 2011-01-26 | — | — | CN | disclosed |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2242755-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089352-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | ROCK1 1141/4885CDC42BPB 233/4885ROCK2 1355/4885 |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | ROCK1 1216/4885CDC42BPB 246/4885ROCK2 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.